Fate Therapeutics (FATE) Restructuring Costs (2023)

Fate Therapeutics' (FATE) quarterly Restructuring Costs came in at $2.0 million in Q1 2023.

Fate Therapeutics (FATE) Restructuring Costs (2023) Analysis & Trends

Fate Therapeutics (FATE) has 1 years of Restructuring Costs data on file, last reported at $2.0 million in Q1 2023.

Quarterly Restructuring Costs changed N/A year-over-year to $2.0 million in Q1 2023, while the trailing twelve-month figure through Dec 2023 was $2.0 million (changed N/A YoY) and the FY2023 annual result came in at $2.0 million, changed N/A from the prior year.
Restructuring Costs held at $2.0 million in Q1 2023.
In the past five years, Restructuring Costs ranged from a high of $2.0 million in Q1 2023 to a low of $2.0 million in Q1 2023.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Fate Therapeutics	298.82 Mn	298.82 Mn	-

Historic Data

Download Data

Date	Value
Mar 31, 2023	2.00 Mn